During drug discovery and development, assessing your lead molecule’s off-target liabilities and identifying mechanisms of toxicity are critical to a successful path to IND. Capture Compound® Mass Spectrometry (CCMS), a chemoproteomics platform, is an analytical technique that enables identification of specific drug-protein interactions.

In this case study webinar, learn how CCMS was applied to generate a comprehensive interaction profile including primary target and specific-binding off-targets. We’ll describe how Charles River used the platform to identify off-targets causing hepatotoxicity of Tolcapone.


  • Sarah Almond, MSc, Group Leader, Integrated Biology
  • Gemma Hardman, PhD, Scientist, Integrated Biology